Synairgen plc

('Synairgen' or the 'Company')

Result of General Meeting and Total Voting Rights

Southampton, UK - 16 January 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that, at the General Meeting held earlier today, all resolutions as set out in the Circular dated 20 December 2024, were duly passed by shareholders on a poll.

A summary of the votes received for the General Meeting will be made available shortly on the Company's website at https://www.synairgen.com/investors/aim-rule-26.

Accordingly, the Company has raised total gross proceeds of £18 million from the Subscription by TFG Asset Management (on behalf of the Relevant Funds).

Application has been made for a total of 900,000,000 New Ordinary Shares to be issued pursuant to the Subscription, to be admitted to trading on AIM.  It is expected that Admission and dealings in the 900,000,000 New Ordinary Shares will commence at 8.00 a.m. on 17 January 2025.

Following Admission, the Company's issued ordinary share capital will comprise 1,102,660,697 Ordinary Shares, none of which are held in treasury. The above figure of 1,102,660,697 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

As detailed in the Results of Non-Underwritten Fundraising announcement on 15 January 2025, as the Minimum Fundraising Condition was not met the Company intends to apply for the cancellation of its Ordinary Shares from trading on AIM ("Cancellation"). A separate announcement will be made in this regard and a circular will be posted to Shareholders in due course which will contain details of the proposed Cancellation.

Following the conclusion of the General Meeting, Martin Murphy has been appointed as an independent Non-Executive Director of the Company. See separate announcement issued today announcing Martin's appointment.

This announcement should be read in conjunction with the full text of the Circular posted to Shareholders on 20 December 2024, copies of which are available on the Company's website. The same definitions apply throughout this announcement as are applied in the Circular.

For further enquiries, please contact:

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.